Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study

Satō, Kyoko; Hayashi, Tomoshige; Maeda, Isseki; Koh, Hideo; Harita, Nobuko; Uehara, Shinichiro; Onishi, Yukiko; Oue, Keiko; Nakamura, Yoshiko; Endo, Ginji; Kambe, Hiroshi; Fukuda, Kanji

doi:10.1111/cen.12171

Cited by 29 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation of lipid abnormalities with obesity, diabetes as well as with the MetS may also implicate involvement of BChE. Higher levels of BChE activity are found in the serum of patients with obesity, diabetes and hyperlipidemias, especially marked increases in VLDL-C [21][22][23] as compared with healthy individuals. Furthermore, induction of obesity or diabetes in animal models is associated with increase in serum TG, BChE activity and rHDL-C levels.…”

Section: Discussionmentioning

confidence: 99%

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

et al. 2014

View full text Add to dashboard Cite

Abdominal obesity (AO) has a strong correlation with cardiovascular disease and has been linked to Alzheimer's disease and type 2 diabetes. We investigated the association between AO and elevated serum butyrylcholinesterase (BChE) activity, insulin resistance and the serum lipid profile, including triglyceride (TG), HDLcholesterol (HDL-C) and LDL-cholesterol (LDL-C) levels in AO and non-AO women subjects. A total of 500 AO subjects (age 49.1 ± 10.5 years), and 142 non-AO women subjects (age 49.9 ± 11.9 years) were enrolled for the general biochemistry tests, serum BChE, fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR). Body mass index, waist circumference, Blood pressure (BP), plasma glucose (Glu), triglyceride (TG), BChE, insulin, HOMA-IR were significantly higher and HDL-C levels were significantly lower in AO subjects (p \ 0.05). Waist circumference was significantly correlated with BP, Glu, TG, BChE, insulin and HOMA-IR in AO subjects. Multiple logistic regression demonstrated that AO was associated with elevated BChE, HOMA-IR, hypertension and reduced HDL-C after adjusting for these variables. AO is associated with elevated BChE, insulin resistance, HT and reduced HDL-C. These may predict the development of type 2 diabetes mellitus and may be associated with cognitive disorder in the future, both are mediated through insulin resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Moreover, levels of β-amyloid are on average about 2-times higher in AD patients compared to normal, healthy subjects [42, 43]. Likewise, the activities of both AChE and BuChE are found to be higher in diabetic patients versus normal controls [44, 45]. This means that abnormal plasma levels of AChE and BuChE may serve as markers to predict the development of T2DM and AD in addition to serving as therapeutic targets [46].…”

Section: Targeting Ache and Buche To Manage Ad And T2dmmentioning

confidence: 99%

Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus

Mushtaq¹,

Greig²,

Khan³

et al. 2014

CNSNDDT

249

175

View full text Add to dashboard Cite

Both Alzheimer’s disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of β-amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Altered levels of AChE and BuChE both in AD as well as in T2DM imply that those two enzymes may be playing a pivotal role in the pathogenesis of the two disorders. AD and T2DM are both characterized by elevated levels of AChE and BuChE in the plasma. On the other hand, in AD the brain levels of AChE go down while those of BuChE go up, resulting in deregulation in balance between AChE and BuChE. This imbalance and change in the AChE/BuChE ratio causes cholinergic deficit in the brain, i.e. deficiency in the brain neurotransmitter acetylcholine. With better understanding of the inter-relationship of AChE and BuChE levels in normality as well as abnormality, AD and T2DM can be effectively treated. Thus, general cholinesterase inhibitors that inhibit both AChE and BuChE as well as highly selective BuChE inhibitors may have potential therapeutic benefits in the treatment of AD and other related dementias.

show abstract

“…; Sato et al. ), further suggesting the BChE may be involved in some compensatory mechanisms in response to metabolic challenges.…”

Section: Discussionmentioning

confidence: 99%

Reduced vagal control of the heart in high-fat diet mice: a potential role of increased butyrylcholinesterase

et al. 2015

View full text Add to dashboard Cite

Suppressed parasympathetic function is commonly present in cardiovascular diseases, aging, obesity, and various other health conditions. Impaired parasympathetic action is known as a detrimental factor and contributes to the adverse outcomes in these conditions. However, the underlying mechanisms remain to be fully addressed. In this study, using high-fat diet (HFD)-induced obese mice as a model, the potential peripheral mechanisms underlying the impaired parasympathetic vagal control of the heart was examined. The HFD induced obesity and metabolic disorder in mice. These obese mice exhibited an attenuated response in heart rate to vagal stimulation, indicating impairment of peripheral parasympathetic activity in the heart. In cholinergic function-related proteins in the atria, protein levels of choline transporter and vesicular acetylcholine transporter were not decreased but increased, and type 2 muscarinic receptors showed a trend toward a reduction in HFD mice atria as compared with regular diet (RD) mice controls. While the protein level of acetylcholinesterase was not different, butyrylcholinesterase (BChE) protein level showed a twofold increase in HFD mice atria as compared with RD mice. Functionally, inhibition of BChE activity partially and significantly improved the attenuated response in heart rate to vagal stimulation in HFD mice. Collectively, these data suggest that increased BChE activity in the atria may contribute to the decreased parasympathetic function in HFD-induced obese mice.

show abstract

Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study

Abstract: Elevated serum butyrylcholinesterase was independently associated with an increased risk of future type 2 diabetes.

Cited by 29 publications

References 24 publications

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus

Reduced vagal control of the heart in high-fat diet mice: a potential role of increased butyrylcholinesterase

Contact Info

Product

Resources

About

Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study

Abstract: Elevated serum butyrylcholinesterase was independently associated with an increased risk of future type 2 diabetes.

Cited by 29 publications

References 24 publications

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels

Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer&#39;s Disease and Type 2 Diabetes Mellitus

Reduced vagal control of the heart in high-fat diet mice: a potential role of increased butyrylcholinesterase

Contact Info

Product

Resources

About

Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus